Home NDC 64725-3920 Geodon
Product NDC 64725-3920
11-digit product format 647253920
Labeler code 64725
Product ID 64725-3920_00a908e6-006f-489e-bf83-f565f9f320c2
Type HUMAN PRESCRIPTION DRUG
Nonproprietary name ziprasidone mesylate
Dosage form INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION
Route INTRAMUSCULAR
Labeler TYA Pharmaceuticals
Application NDA020919
Marketing category NDA
Marketing start 2003-12-23
Marketing end 0000-00-00
Substance ZIPRASIDONE MESYLATE
Active strength 20 mg/mL
Pharmacologic classes Atypical Antipsychotic [EPC]
NDC exclude flag E
Listing certified through 2017-12-31
Current FDA listing Historical FDA.report record Observed NDC auxiliary status history# This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.
Historic NDC status page 1 of 1 · 44 matching rows.
View current auxiliary records. · View the auxiliary file history.
Captured / source date, Dataset, Scope table Captured / source date Dataset Scope Package NDC Code Status Snapshot Source SHA-256 2025-12-14 17:58 UTC · source 2025-12-05 excluded product product I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-12-14 17:58 UTC · source 2025-12-05 excluded package package 64725-3920-1 I Inactivated by FDA d630ba8d3edf…732f749b63fb…2025-08-27 00:01 UTC · source 2025-08-26 excluded product product I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-08-27 00:01 UTC · source 2025-08-26 excluded package package 64725-3920-1 I Inactivated by FDA f5e01cc5f278…a2eaf40c39c3…2025-04-01 02:39 UTC · source 2025-03-31 excluded product product I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-04-01 02:39 UTC · source 2025-03-31 excluded package package 64725-3920-1 I Inactivated by FDA 2ef7874e63bc…57b86245f4fa…2025-03-28 20:22 UTC · source 2025-03-28 excluded product product I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-28 20:22 UTC · source 2025-03-28 excluded package package 64725-3920-1 I Inactivated by FDA a1b67e2a42f9…c4cf2c586c0d…2025-03-22 03:12 UTC · source 2025-03-21 excluded product product I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-22 03:12 UTC · source 2025-03-21 excluded package package 64725-3920-1 I Inactivated by FDA cfe11265f3b6…090c488252e2…2025-03-10 12:48 UTC · source 2025-03-10 excluded product product I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-03-10 12:48 UTC · source 2025-03-10 excluded package package 64725-3920-1 I Inactivated by FDA cdf11ea48f46…ba0047e9e063…2025-02-02 03:52 UTC · source 2025-01-31 excluded product product I Inactivated by FDA 302b2466d912…e7b80fea0513…2025-02-02 03:52 UTC · source 2025-01-31 excluded package package 64725-3920-1 I Inactivated by FDA 302b2466d912…e7b80fea0513…2025-01-20 13:05 UTC · source 2025-01-20 excluded product product I Inactivated by FDA ed331223b511…672a5bd82f5f…2025-01-20 13:05 UTC · source 2025-01-20 excluded package package 64725-3920-1 I Inactivated by FDA ed331223b511…672a5bd82f5f…2025-01-11 03:41 UTC · source 2025-01-10 excluded product product I Inactivated by FDA 0efc9e666f02…f202fb6c5f17…2025-01-11 03:41 UTC · source 2025-01-10 excluded package package 64725-3920-1 I Inactivated by FDA 0efc9e666f02…f202fb6c5f17…2024-11-09 02:27 UTC · source 2024-11-08 excluded product product I Inactivated by FDA ad56d346431e…cc804d4bbf1e…2024-11-09 02:27 UTC · source 2024-11-08 excluded package package 64725-3920-1 I Inactivated by FDA ad56d346431e…cc804d4bbf1e…2024-10-04 04:10 UTC · source 2024-10-03 excluded product product I Inactivated by FDA 367a005e9d99…383a685ebd0f…2024-10-04 04:10 UTC · source 2024-10-03 excluded package package 64725-3920-1 I Inactivated by FDA 367a005e9d99…383a685ebd0f…2024-07-10 04:00 UTC · source 2024-07-09 excluded product product I Inactivated by FDA 557ba5c1ecfa…9c80585c8c6e…2024-07-10 04:00 UTC · source 2024-07-09 excluded package package 64725-3920-1 I Inactivated by FDA 557ba5c1ecfa…9c80585c8c6e…2024-05-28 21:12 UTC · source 2024-05-28 excluded product product I Inactivated by FDA 8af77b9d5b6f…d9bbb34c5368…2024-05-28 21:12 UTC · source 2024-05-28 excluded package package 64725-3920-1 I Inactivated by FDA 8af77b9d5b6f…d9bbb34c5368…2024-05-15 03:39 UTC · source 2024-05-14 excluded product product I Inactivated by FDA 834df4deac94…adcc014656a3…2024-05-15 03:39 UTC · source 2024-05-14 excluded package package 64725-3920-1 I Inactivated by FDA 834df4deac94…adcc014656a3…2024-03-11 06:39 UTC · source 2024-03-08 excluded product product I Inactivated by FDA 1332a3947898…d4bfe170f9cd…2024-03-11 06:39 UTC · source 2024-03-08 excluded package package 64725-3920-1 I Inactivated by FDA 1332a3947898…d4bfe170f9cd…2022-08-30 03:57 UTC · source 2022-08-29 excluded product product I Inactivated by FDA fb8cb913e6d1…eb8c232b6be0…2022-08-30 03:57 UTC · source 2022-08-29 excluded package package 64725-3920-1 I Inactivated by FDA fb8cb913e6d1…eb8c232b6be0…2022-04-09 23:13 UTC · source 2022-04-08 excluded product product I Inactivated by FDA 86f5da6cb304…a595104c45d7…2022-04-09 23:13 UTC · source 2022-04-08 excluded package package 64725-3920-1 I Inactivated by FDA 86f5da6cb304…a595104c45d7…2022-04-04 05:40 UTC · source 2022-04-01 excluded product product I Inactivated by FDA bd6a592717d7…303034d00443…2022-04-04 05:40 UTC · source 2022-04-01 excluded package package 64725-3920-1 I Inactivated by FDA bd6a592717d7…303034d00443…2021-12-27 23:28 UTC · source 2021-12-27 excluded product product I Inactivated by FDA 8dfbde2a14a4…c9ff85d89658…2021-12-27 23:28 UTC · source 2021-12-27 excluded package package 64725-3920-1 I Inactivated by FDA 8dfbde2a14a4…c9ff85d89658…2020-12-18 03:04 UTC · source 2020-12-17 excluded product product I Inactivated by FDA e2bbac7714bc…27bdfed8d636…2020-12-18 03:04 UTC · source 2020-12-17 excluded package package 64725-3920-1 I Inactivated by FDA e2bbac7714bc…27bdfed8d636…2020-06-10 20:45 UTC · source 2020-06-10 excluded product product I Inactivated by FDA 9bebd1f3094a…5416666fcb17…2020-06-10 20:45 UTC · source 2020-06-10 excluded package package 64725-3920-1 I Inactivated by FDA 9bebd1f3094a…5416666fcb17…2019-12-08 06:16 UTC · source 2019-12-05 excluded product product E Excluded after deficient or non-compliant submission was not corrected 110d247fa046…a55b01930146…2019-12-08 06:16 UTC · source 2019-12-05 excluded package package 64725-3920-1 E Excluded after deficient or non-compliant submission was not corrected 110d247fa046…a55b01930146…
Source provenance: Browse the complete Orange Book source catalog · source snapshot 1 .
Orange Book products# Current product rows page 1 of 1 · 1 matching rows.
Application-product, Trade name, Ingredient table Application-product Trade name Ingredient Strength Dosage form / route TE codes RLD / RS Approval date N020919-001 GEODON ZIPRASIDONE MESYLATE EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21
Therapeutic equivalence codes# Current TE-code rows page 1 of 1 · 1 matching rows.
Application-product, TE code table Application-product TE code N020919-001 AP
Observed Orange Book product history# Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
Product history page 1 of 2 · 41 observed states.
Captured, Edition, Application-product table Captured Edition Application-product Trade name Strength Dosage form / route Product TE source text RLD / RS Approval date Source SHA-256 2026-02-19 14:30 UTC 2026-02 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 011fe1cb6892…2025-12-14 10:44 UTC · 2 captures of this ZIP 2025-12 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 31067a03dcf5…2025-08-23 18:47 UTC 2025-08 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 6a471c1ec25d…2025-03-22 03:13 UTC · 3 captures of this ZIP 2025-03 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 fd3edfee7708…2025-02-26 10:13 UTC · 3 captures of this ZIP 2025-02 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 b8a1b40f171c…2025-01-19 17:59 UTC · 7 captures of this ZIP 2025-01 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 03ed91905a0d…2024-12-13 21:23 UTC · 2 captures of this ZIP 2024-12 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 2680178bc6a6…2024-09-14 05:58 UTC · 2 captures of this ZIP 2024-09 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 5bbf6a4d5a75…2024-11-08 22:44 UTC · 3 captures of this ZIP 2024-11 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 d8e5a09893c0…2024-10-29 15:01 UTC 2024-10 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 d06236e962d9…2024-08-13 05:28 UTC · 3 captures of this ZIP 2024-08 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 79d66fd596c7…2024-07-13 05:37 UTC · 2 captures of this ZIP 2024-07 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 301d65b070ca…2024-06-18 03:08 UTC · 5 captures of this ZIP 2024-06 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 1e350fbaab3a…2024-05-31 18:47 UTC 2024-05 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 8072bd15b7f6…2022-06-29 02:47 UTC · 2 captures of this ZIP 2022-06 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 5c6f7cd8ea54…2022-04-08 23:34 UTC 2022-04 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 5d02ea3f76ae…2022-04-04 05:41 UTC 2022-04 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 4b0b4de00fa7…2019-12-13 00:20 UTC 2019-12 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR RLD, RS 2002-06-21 74a2ff9319b5…2022-03-09 01:35 UTC 2022-03 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR AP RLD, RS 2002-06-21 bb7c543d1eb4…2021-12-28 21:50 UTC 2021-12 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR AP RLD, RS 2002-06-21 782e0a99824c…2021-05-05 16:15 UTC · 3 captures of this ZIP 2021-05 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR AP RLD, RS 2002-06-21 87673890dc5c…2021-03-12 10:30 UTC 2021-03 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR AP RLD, RS 2002-06-21 5aa47cf7b7d7…2020-12-22 03:56 UTC 2020-12 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR AP RLD, RS 2002-06-21 8869cabd3fbd…2020-11-12 02:37 UTC 2020-11 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR AP RLD, RS 2002-06-21 c0c555d07b60…2019-12-14 00:12 UTC 2019-12 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR RLD, RS 2002-06-21 3f01610625f2…2019-09-15 20:21 UTC 2019-09 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR RLD, RS 2002-06-21 b00525d2431f…2019-07-19 19:46 UTC 2019-07 N020919-001 GEODON EQ 20MG BASE/ML INJECTABLE / INTRAMUSCULAR RLD, RS 2002-06-21 ea99ee380514…2024-03-16 18:09 UTC · 4 captures of this ZIP 2024-03 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 6a51e52b5d6a…2024-02-18 07:12 UTC 2024-02 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 1c564ffb4f44…2023-12-20 04:57 UTC 2023-12 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 ea1830bbd6c7…2023-11-28 05:40 UTC · 2 captures of this ZIP 2023-11 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 a72a2bbeb626…2023-10-25 00:34 UTC · 2 captures of this ZIP 2023-10 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 9b2671bbb829…2023-07-15 15:27 UTC · 2 captures of this ZIP 2023-07 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 a67488948f0b…2023-06-13 01:57 UTC · 3 captures of this ZIP 2023-06 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 3f0d92c62455…2023-05-13 08:27 UTC 2023-05 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 053a50430f4f…2023-01-26 05:58 UTC 2023-01 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 3bdfa0b2c4d7…2022-11-12 20:34 UTC · 5 captures of this ZIP 2022-11 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 3a93d1ddd44b…2022-10-28 04:53 UTC 2022-10 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 f41ea6bd6efb…2022-09-29 23:25 UTC 2022-09 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 e64feba35796…2022-07-09 03:26 UTC · 3 captures of this ZIP 2022-07 N020919-001 GEODON EQ 20MG BASE/VIAL POWDER / INTRAMUSCULAR AP RLD, RS 2002-06-21 cb3db0bc1861…
Observed Orange Book normalized TE history# DailyMed Product Concepts# FDA-Initiated Inactive NDC Indexing# DailyMed Package Descriptions# Package NDC, Product, Description table Package NDC Product Description Form Quantity Strength SPL version 64725-3920-1 Geodon 10 mL in 1 CARTON INJECTION, POWDER, LYOPHILIZED, 10 2
DailyMed Socrata Ingredients# Ingredient, Type, UNII table Ingredient Type UNII DailyMed label SPL version Uploaded ZIPRASIDONE MESYLATE ACTIVE INGREDIENT 3X6SAX83JZ GEODON (ZIPRASIDONE MESYLATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [TYA PHARMACEUTICALS] 2 ZIPRASIDONE ACTIVE MOIETY 6UKA5VEJ6X GEODON (ZIPRASIDONE MESYLATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [TYA PHARMACEUTICALS] 2 METHANESULFONIC ACID INACTIVE INGREDIENT 12EH9M7279 GEODON (ZIPRASIDONE MESYLATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [TYA PHARMACEUTICALS] 2 SULFOBUTYLETHER .BETA.-CYCLODEXTRIN INACTIVE INGREDIENT 2PP9364507 GEODON (ZIPRASIDONE MESYLATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [TYA PHARMACEUTICALS] 2
DailyMed Dashboard NDC Coverage# NDC, Dashboard title, SPL version table NDC Dashboard title SPL version Validation Dashboard ZIP 64725-3920 GEODON (ZIPRASIDONE MESYLATE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [TYA PHARMACEUTICALS] 2 Legacy NDC, 1 package rows 20141031_136aeec3-b918-4157-b2a7-dd615e36183f.zip
openFDA label cross-check# OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Matched openFDA labels page 1 of 1 · 2 matching rows.
DailyMed RxNorm Mappings# Packages# Package NDC, 11-digit format, Description table Package NDC 11-digit format Description Units Status 64725-3920-1 64725392001 10 mL in 1 CARTON 10 ml Historical